doi: 10.3389/fphar.2025.1546041 Received 16 December 2024 Accepted 13 May 2025 Published 29 May 2025 Volume 16 - 2025 Edited by Massoud Ranjbar, Bu-Ali Sina University, Iran Reviewed by Yuxiang Fei, China Pharmaceutical University, China Liuqing Yang, Hangzhou Hospital of Traditional Chinese Medicine, China Updates Copyright 2025 Ju, Zhao, Li, Zhang, Xiang and Lian
8-year trends in obesity, type 2 diabetes, and glucagon-like peptide-1 (GLP-1) use in patients with obstructive sleep apnea
PlexusDx supports precision dosing through licensed 503A compounding pharmacies, where pharmacist-to-prescriber communication helps prevent dosing errors and ensures you receive appropriate starting doses based on medical history
Apart from potentially improving ED symptoms and testosterone levels via inducing weight loss, semaglutide may also help reduce inflammation and atherosclerosis progression [36, 37]